SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Strasburger C.)
 

Search: WFRF:(Strasburger C.) > (2000-2004) > Long-term treatment...

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

van der Lely, A J (author)
Hutson, R K (author)
Trainer, P J (author)
show more...
Besser, G M (author)
Barkan, A L (author)
Katznelson, L (author)
Klibanski, A (author)
Herman-Bonert, V (author)
Melmed, S (author)
Vance, M L (author)
Freda, P U (author)
Stewart, P M (author)
Friend, K E (author)
Clemmons, D R (author)
Johannsson, Gudmundur, 1960 (author)
Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för kroppssammansättning och metabolism,Institute of Internal Medicine, Dept of Body Composition and Metabolism
Stavrou, S (author)
Cook, D M (author)
Phillips, L S (author)
Strasburger, C J (author)
Hackett, S (author)
Zib, K A (author)
Davis, R J (author)
Scarlett, J A (author)
Thorner, M O (author)
show less...
 (creator_code:org_t)
2001
2001
English.
In: Lancet (London, England). - 0140-6736. ; 358:9295, s. 1754-9
Related links:
https://gup.ub.gu.se...
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days.Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis.Mean serum IGF-1 concentrations fell by at least 50%: 467 mg/L (SE 24), 526 mg/L (29), and 523 mg/L (40) in patients treated for 6, 12 and 18 months, respectively (p<0.001), whereas growth hormone increased by 12.5 mg/L (2.1), 12.5 mg/L (3.0), and 14.2 mg/L (5.7) (p<0.001). Of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration. In patients withdrawn from pegvisomant (n=45), serum growth hormone concentrations were 8.0 mg/L (2.5) at baseline, rose to 15.2 mg/L (2.4) on drug, and fell back within 30 days of withdrawal to 8.3 mg/L (2.7). Antibodies to growth hormone were detected in 27 (16.9%) of patients, but no tachyphylaxis was seen. Serum insulin and glucose concentrations were significantly decreased (p<0.05). Two patients experienced progressive growth of their pituitary tumours, and two other patients had increased alanine and asparate aminotransferase concentrations requiring withdrawal from treatment. Mean pituitary tumour volume in 131 patients followed for a mean of 11.46 months (0.70) decreased by 0.033 cm(3) (0.057; p=0.353).Pegvisomant is an effective medical treatment for acromegaly.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Keyword

Acromegaly
drug therapy
Adult
Blood Glucose
drug effects
Cohort Studies
Drug Administration Schedule
Female
Growth Hormone
blood
Human Growth Hormone
analogs & derivatives
Humans
Insulin
blood
Insulin-Like Growth Factor I
metabolism
Male
Middle Aged
Receptors
Somatotropin
antagonists & inhibitors
therapeutic use

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view